• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Raynauds Disease - Pipeline Review, H2 2012 Product Image

Raynauds Disease - Pipeline Review, H2 2012

  • ID: 2335344
  • November 2012
  • 37 pages
  • Global Markets Direct

Raynauds Disease – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Raynauds Disease - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Raynauds Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Raynauds Disease. Raynauds Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Raynauds Disease.
- A review of the Raynauds Disease products under development by companies and universities/research institutes READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Raynauds Disease Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Raynauds Disease 7
Raynauds Disease Therapeutics under Development by Companies 9
Raynauds Disease Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Raynauds Disease Therapeutics – Products under Development by Companies 15
Raynauds Disease Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Raynauds Disease Therapeutics Development 17
NexMed, Inc. 17
Azevan Pharmaceuticals, Inc. 18
Raynauds Disease – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
SRX-251 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
udenafil - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
fasudil - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
alprostadil - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
onabotulinumtoxinA - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Raynauds Disease Therapeutics – Drug Profile Updates 31
Raynauds Disease Therapeutics – Discontinued Products 32
Raynauds Disease Therapeutics - Dormant Products 33
Raynauds Disease – Product Development Milestones 34
Featured News & Press Releases 34
May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud's Phenomenon 34
Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa 34
Sep 22, 2010: FDA Guides Apricus Bio On RayVa's Approvability For Raynaud's Syndrome Secondary To Scleroderma 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Number of Products Under Development for Raynauds Disease, H2 2012 7
Products under Development for Raynauds Disease – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
NexMed, Inc., H2 2012 17
Azevan Pharmaceuticals, Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Raynauds Disease Therapeutics – Drug Profile Updates 31
Raynauds Disease Therapeutics – Discontinued Products 32
Raynauds Disease Therapeutics – Dormant Products 33

List of Figures
Number of Products under Development for Raynauds Disease, H2 2012 7
Products under Development for Raynauds Disease – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos